Towards Health & Prosperity… An Update on an Action Plan to Help Attract More Clinical Trials to Canada (December 2012) square

Towards Health & Prosperity… An Update on an Action Plan to Help Attract More Clinical Trials to Canada (December 2012)

On the first anniversary of the 2011 Clinical Trials Summit, ACAHO, Rx&D, and CIHR reflect on the year since the 2011 Summit and give a six-month progress report since the Action Plan’s release. Author/Presenter: Rx&D, CIHR, ACAHO

To Your Health & Prosperity – An Action Plan to Help Attract More Clinical Trials to Canada (March 30, 2012) square

To Your Health & Prosperity – An Action Plan to Help Attract More Clinical Trials to Canada (March 30, 2012)

Action plan from the 2011 National Clinical Trials Summit. It is the third and final paper in a trilogy of papers from the clinical trial summit hosted by Rx&D, CIHR, and ACAHO.

Background Document – Starting the Conversation​​ square

Background Document – Starting the Conversation​​

Background document prepared for the 2011 National Clinical Trial Summit. Author/Presenter: RX&D, CIHR, ACAHO

Strategic Infrastructure Issues 2 square

Strategic Infrastructure Issues 2

A discussion of international clinical trial infrastructure models and what is necessary to improve Canada’s competitiveness in clinical research. Author/Presenter: Dr. Jean-Marie Leclerc, Chief Scientific Officer and Senior Vice President, Clinical and Regulatory Affairs, Novartis  

Strategic Infrastructure Issues 1 square

Strategic Infrastructure Issues 1

A discussion of international clinical trial infrastructure models and what is necessary to improve Canada’s competitiveness in clinical research. Author/Presenter: Dr. Rob McMaster, Vice President Research, Vancouver Coastal Health  

Cost Issues square

Cost Issues

Presentation by L. Bennett, and Dr. S. Choudhri at the 2011 National Clinical Trials Summit on Cost Structure. Author/Presenter: Linda Bennett, Executive Director, Canadian Rheumatology Research Consortium & Dr. Shurjeel Choudhri, Senior Vice-President and Head, Medical and Scientific Affairs, Bayer Inc.

Admininstrative Issues square

Admininstrative Issues

Presentation by Dr. N. Maresky & K. Arts at the 2011 National Clinical Trials Summit on Improving Administrative Aspects of the Canadian Clinical Trials Environment. Author/Presenter: Dr. Neil Maresky, Vice-President, Scientific Affairs, AstraZeneca Inc. & Karen Arts, Director, Business Development, Clinical Trials, Ontario Institute for Cancer Research & Co-Founder and Chair of Board of Directors […]

Recruitment & Retention square

Recruitment & Retention

Presentation by D. Simmons & S. Gazel at the 2011 National Clinical Trials Summit on Patient Recruitment Retention and Follow-up Author/Presenter: Diane Simmons, President and CEO, Center for Information and Study on Clinical Research Participation & Sandra Gazel, Associate Director, Clinical Operations, Abbott

Streamlining Ethics Review square

Streamlining Ethics Review

Presentation by L. Barrett-Smith & Dr. S. Glezer at the 2011 National Clinical Trials Summit on Streamlining Ethics Review in Canada, titled: A matter of Balance Author/Presenter: Linda Barrett-Smith, Drector, Research Ethics & Alberta Clinical Research Consortium (ACRC) & Dr. Stanislav Glezer, Vice-President Medical Affairs, Sanofi-Aventis

Summary, Implications and Next Steps square

Summary, Implications and Next Steps

Keynote address by Dr. A. Slutsky at the 2011 National Clinical Trials Summit titled: Starting the Conversation…A SWOT, So What, & Now What? Summary, Implications & Next Steps Author/Presenter: Dr. Arthur Slutsky, ACAHO Research Co-Chair & Vice President Research, St. Michael’s Hospital

Matrix on current initiatives in Canada square

Matrix on current initiatives in Canada

Keynote address by Dr. J. Rouleau at the 2011 National Clinical Trials Summit titled: SPOR: A Major Strategy for the Development of Clinical Research in Canada Author/Presenter: Dr. Jean Rouleau, Scientific Director, CIHR Institute of Circulatory and Respiratory Health

Globalization of clinical research & metrics survey results square

Globalization of clinical research & metrics survey results

Keynote address by N. Laberge at the 2011 National Clinical Trials Summit titled: Globalization of Clinical Research: Trends & Implications for Canada Author/Presenter: Normand Laberge, Vice-President, Regulatory and Scientific Affairs, Canada’s Research-based Pharmaceutical Companies (Rx&D)

Opening Remarks – ACAHO square

Opening Remarks – ACAHO

Opening Remarks by G. Brimacombe, President & CEO of ACAHO at the 2011 Clinical Trials Summit Author/Presenter: Mr. Glenn Brimacombe, President & CEO, ACAHO

Opening Remarks square

Opening Remarks

Opening Remarks by R. Williams, President of Rx&D at the 2011 National Clinical Trials Summit. Author/Presenter: Russell Williams, President, Canada’s Research-Based Pharmaceutical Companies (Rx&D)

Canadian Clinical Trial Summit – Starting the Conversation (September 15, 2011) square

Canadian Clinical Trial Summit – Starting the Conversation (September 15, 2011)

On September 15, 2011, ACAHO, Canada’s Research-Based Pharmaceutical Companies (Rx&D) and the Canadian Institutes of Health Research (CIHR) co-hosted a National Clinical Trial Summit designed to help reinvigorate and re-establish Canada’s tradition of excellence in clinical trials, bringing together over 120 experts from patient care sites, research, academia, government and industry in a first time […]

Investment Case – “Clinical Trials – The Canadian Advantage” – 2018 square

Investment Case – “Clinical Trials – The Canadian Advantage” – 2018

The case for running clinical trials in Canada, advantages and information (English, pdf format) Author/Presenter: CCTCC

Investment Case – “Clinical Trials – The Canadian Advantage” – 2018 – French

Investment Case – “Clinical Trials – The Canadian Advantage” – 2018 – French

The case for running clinical trials in Canada, advantages and information (French, ppt format) Author/Presenter: CCTCC https://www.cctcc.ca/wp-content/uploads/2018/08/CCTCC_InvestmentCase_Updated-June-2018_French.pptx

Investment Case – “Clinical Trials – The Canadian Advantage” – 2018

Investment Case – “Clinical Trials – The Canadian Advantage” – 2018

The case for running clinical trials in Canada, advantages and information (English, ppt format) Author/Presenter: CCTCC https://www.cctcc.ca/wp-content/uploads/2018/02/CCTCC_CT-Investment-Case_June-2017_Final1.pptx

2018 Strategic Planning Report: A pan-Canadian Clinical Trial Strategy

2018 Strategic Planning Report: A pan-Canadian Clinical Trial Strategy

Report and Key Result areas from the Strategic Planning process initiated in 2017 and facilitated by Intersol. Author/Presenter: CCTCC/Intersol

Proposed Data Collection for mCTA metrics draft

Proposed Data Collection for mCTA metrics draft

Proposed metrics on the usage of the mCTA Author/Presenter: CCTCC https://www.cctcc.ca/wp-content/uploads/2018/08/Proposed-Data-collection-for-mCTA-metrics-draft.xlsx

mCTA version 8 use letter final

mCTA version 8 use letter final

Letter template for sites and sponsors to confirm their adoption of the mCTA Author/Presenter: CCTCC https://www.cctcc.ca/wp-content/uploads/2018/08/mCTA-version-8-use-letter-final-draft.docx

mCTA_Version 8_PP Slides (pp)

mCTA_Version 8_PP Slides (pp)

Informational slides on the history and use of the mCTA (powerpoint format) Author/Presenter: CCTCC https://www.cctcc.ca/wp-content/uploads/2018/08/mCTA_Version-8_PP-Slides.pptx

mCTA_Version 8_PP Slides (pdf)

mCTA_Version 8_PP Slides (pdf)

Informational slides on the history and use of the mCTA (pdf format) Author/Presenter: CCTCC

mCTA Version 8_Final_June 2017 (Word)

mCTA Version 8_Final_June 2017 (Word)

Version 8 of the mCTA contract (Word format) Author/Presenter: CCTCC https://www.cctcc.ca/wp-content/uploads/2018/08/mCTA-Version-8_Final_June-2017.docx

Drivers for the FMV Initiative (Sites) square

Drivers for the FMV Initiative (Sites)

Presentation of key drivers for the Fair Market Value initiative from the site perspective Author/Presenter: CCTCC

CCTCC & Health Canada Response to REB WG Final Recommendations

CCTCC & Health Canada Response to REB WG Final Recommendations

Joint response by the CCTCC and Health Canada to the final recommendations of the CCTCC REB Accreditation WG Author/Presenter: CCTCC & Health Canada

CCTCC REB Accreditation WG Final Recommendations

CCTCC REB Accreditation WG Final Recommendations

The final report and recommendations of the CCTCC REB Accreditation WG established in April 2015 Author/Presenter: CCTCC REB Accreditation Working Group

REB Accreditation WG Interim Report

REB Accreditation WG Interim Report

The interim report of the CCTCC REB Accreditation WG established in April 2015 Author/Presenter: CCTCC REB Accreditation Working Group

Clinical trials transparency in the Americas: the need to coordinate regulatory spheres

Clinical trials transparency in the Americas: the need to coordinate regulatory spheres

BMJ 2018; 362:k2493 Author/Presenter: Trudo Lemmens, professor and Scholl chair in health law and policy, and Carlos Herrera Vacaflor, researcher

How does Canada’s clinical trials database Measure Up?

How does Canada’s clinical trials database Measure Up?

Article in Macleans on what the Health Canada clinical trials database means for health transparency Author/presenter: Julia Belluz, Senior Editor, Medical Post

Game Changers: Does Canada Have a Place on the Clinical Trial Podium?

Game Changers: Does Canada Have a Place on the Clinical Trial Podium?

Canada’s Innovation Leaders, a RE$EARCH Infosource Inc. Publication Author/Presenter: W. Robert McMaster – Executive Director Vancouver Coastal Health Research

News Release – Clinical Trials Summit – EN square

News Release – Clinical Trials Summit – EN

News Release on the occasion of the 2011 National Clinical Trials Summit Author/Presenter: Rx&D, CIHR, ACAHO

Enhancing the Canadian Clinical Research Environment – The mCTA and Fair Market Value Initiatives

Enhancing the Canadian Clinical Research Environment – The mCTA and Fair Market Value Initiatives

CARA East 2017 Breakout Session Presentation Author/Presenter: Kathryn Nijssen, Initiative Manager, CCTCC and Dex Bilkic, Manager, Study Start-Up & Patient Recruitment, Bayer Canada

Canadian Clinical Trials Coordinating Centre (CCTCC)

Canadian Clinical Trials Coordinating Centre (CCTCC)

Presentation by the CCTCC to the Huntington’s Society on current initiatives Author/Presenter: Elena Aminkova

Canadian Clinical Trials Coordinating Centre (CCTCC)

Canadian Clinical Trials Coordinating Centre (CCTCC)

Presentation by the CCTCC to SOCRA on current initiatives Author/Presenter: Elena Aminkova

16th Clinical Trials in Canada Summit October 5_2016

16th Clinical Trials in Canada Summit October 5_2016

Presentation by Elena Aminkova at 16th Clinical Trials in Canada Summit 2016 Author/Presenter: Elena Aminkova, CCTCC

Initiatives for Enhancing the Canadian Clinical Research Environment

Initiatives for Enhancing the Canadian Clinical Research Environment

Presentation by Dr. Shurjeel Choudhri at the 2016 Evolution Summit Author/Presenter: Dr. Shurjeel Choudhri, Senior Vice President & Head, Medical and Scientific Affairs, Bayer Inc. Chair, Executive Committee, CCTCC

“Clinical Trials – The Canadian Advantage” panel

“Clinical Trials – The Canadian Advantage” panel

Bio 2016 Panel Discussion, San Francisco, CA Author/Presenter: CCTCC, Panel Moderated by Mr. Michel Perron – Vice-President, External Affairs and Business Development, CIHR

SPOR SHRER Report Appendix D

SPOR SHRER Report Appendix D

SPOR SHRER Report Appendix D Harmonization Survey Author/Presenter: CIHR SPOR

SPOR SHRER REPORT Appendix C

SPOR SHRER REPORT Appendix C

SPOR SHRER Report Appendix C_1-C_2 Model Elements CT Forms Author/Presenter: CIHR SPOR

Senate of Canada square

Senate of Canada

The Standing Senate Committee on Social Affairs, Science and Technology, November (2012) regarding the state of Clinical Trials in Canada. Author/Presenter: Standing Senate Committee on Social Affairs, Science and Technology – The Honourable Kelvin K. Ogilvie, Chair & The Honourable Art Eggleton, P.C., Deputy Chair

The Advantages of Doing Research in Canada – A Summary of Research and Development Tax incentives

The Advantages of Doing Research in Canada – A Summary of Research and Development Tax incentives

R&D Tax Credits summary published by Invest in Canada Bureau in 2007 Author/Presenter: Invest in Canada Bureau, in consultation with Canada’s Revenue Agency. Initially developed by the S&T Team of the Berlin Canadian Embassy https://www.cctcc.ca/wp-content/uploads/2018/08/advantages.of_.doing_.RD_.in_.canada-2007.pdf